A RCT Study in Schizophrenia Relapse Prevention
THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH HYPOTHESIS A the end of 18 months study duration, patients in the active group enrolled in ITAREPS will demonstrate statistically significantly reduced risk of hospitalization, decreased number of hospitalization days and reduced direct inpatient costs in comparison to control group not using the program.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Prospective, Randomized, Open, Controlled Study With Information and Telecommunication Technology-aided Relapse Prevention Program in Schizophrenia.|
- Primary Objective: The hospitalization-free survival rate at 18 months in active group compared to the control group. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
- Number of psychiatric hospitalization days [ Time Frame: 18months ] [ Designated as safety issue: No ]
- Direct impatient costs [ Time Frame: 18months ] [ Designated as safety issue: No ]
- Direct cost of outpatient antipsychotic medication [ Time Frame: 18months ] [ Designated as safety issue: No ]
- Cumulative exposition to antipsychotic medication in both active ITAREPS and control groups [ Time Frame: 18months ] [ Designated as safety issue: No ]
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
Active Comparator: 20% antisychotic dose increase in prodromes
Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
Other Name: Information Technology Aided Relaps Prevention in Schizophrenia
No Intervention: Treatment as usual
In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
The ITAREPS 2.0 program employs telecommunication and information technologies in order to detect fluctuations in longitudinal mental health status of patient with schizophrenia and thus signalize the very early stages of prodromes preceding relapse. This approach opens an avenue towards early pharmacological intervention. Subjects (150 patients with diagnosis of schizophrenia and schizoaffective disorder and their family members) will be randomized at a 1:1 ratio into the active or control group. Participants from the active group will be completing two separate versions of the 10-item Early Warning Signs Questionnaire (EWSQ) upon a weekly SMS request generated automatically by the system during 18 months study duration. In this group, automatically generated e-mail alert message feedback to the investigator will be activated in case of prodrome detection, prompting investigator to antipsychotic dose increase by 20%. The control (treatment-as-usual) group will not use ITAREPS system.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01885923
|Prague Psychiatric Center|
|Prague, Czech Republic, 18103|
|Study Director:||Filip Spaniel, MD, PhD||Prague Psychiatric Center|